{"commentary":{"count":36,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":19,"podcast":10,"youtube":6,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02420821\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMmotion151","nct_id":"NCT02420821","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=immotion151-nct02420821. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"IMmotion151","arms":[{"description":"Participants will receive both atezolizumab and bevacizumab until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.","label":"Atezolizumab + Bevacizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive sunitinib until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.","label":"Sunitinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2021-12-13","type":"ACTUAL"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":915,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","type":"DRUG"},{"name":"Bevacizumab","type":"DRUG"},{"name":"Sunitinib","type":"DRUG"}],"last_update":"2023-01-30","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-02-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population","timeFrame":"Baseline until documented PD or death, whichever occurred first (until data cut-off date 29 September 2017, up to approximately 24 months)"},{"measure":"Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 in PD-L1-Selected Population","timeFrame":"Baseline until documented PD or death, whichever occurred first (until data cut-off date 29 September 2017, up to approximately 24 months)"},{"measure":"Percentage of Participants Who Died of Any Cause in ITT Population","timeFrame":"Baseline until death from any cause (until data cut-off date 14 February 2020, up to approximately 57 months)"},{"measure":"Overall Survival (OS) in ITT Population","timeFrame":"Baseline until death from any cause (until data cut-off date 14 February 2020, up to approximately 57 months)"}],"references":[{"citation":"Re C, Ince WHJ, Bickley L, Blackmur JP, Ismail MH, Kyeremeh J, Kuusk T, Serrao EM, Jones JO, Stewart GD. Oligoprogressive renal cell carcinoma: What is the role of surgery? BJU Int. 2026 Aug;138(2):219-228. doi: 10.1111/bju.70281. Epub 2026 Apr 13.","pmid":"41969229","type":"DERIVED"},{"citation":"Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.","pmid":"37146227","type":"DERIVED"},{"citation":"Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, Lee JL, Suarez C, Stroyakovskiy D, De Giorgi U, Donskov F, Mellado B, Banchereau R, Hamidi H, Khan O, Craine V, Huseni M, Flinn N, Dubey S, Rini BI. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol. 2022 Feb 1;8(2):275-280. doi: 10.1001/jamaoncol.2021.5981.","pmid":"34940781","type":"DERIVED"},{"citation":"Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Gurney H, Oudard S, Uemura M, Lam ET, Grullich C, Quach C, Carroll S, Ding B, Zhu QC, Piault-Louis E, Schiff C, Escudier B. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naive Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 Jun 1;26(11):2506-2514. doi: 10.1158/1078-0432.CCR-19-2838. Epub 2020 Mar 3.","pmid":"32127394","type":"DERIVED"},{"citation":"Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.","pmid":"31079938","type":"DERIVED"}],"start_date":{"date":"2015-05-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)","url":"https://clinicaltrials.gov/study/NCT02420821"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/immotion151-nct02420821"}